According to news reports this morning, the National Institute for Health and Care Excellence (NICE) in England has changed its tune about covering cabazitaxel (Jevtana) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ NORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, England, NICE | Leave a comment »
New guidance in England has expanded coverage of treatment with abiraterone acetate (Zytiga) + prednisone for men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, coverage, NICE, Zytiga | Leave a comment »
According to an article this morning on the PharmaTimes web site, Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, coverage, enzalutamide, NICE, UK, Xtandi, Zytiga | 3 Comments »
According to a report on the PharmaFile web site, the National Institute for Health and Care Excellence (NICE) in England has rejected Dendreon’s application for coverage of the costs of treatment with sipuleucel-T (Provenge) for the second time in less than a year. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: England, NICE, Provenge, sipuleucel-T | 3 Comments »
As all our regular readers will be well aware, it is not enough, in the UK, for a new cancer drug to be approved for use by the European Union and its European Medicines Agency. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: access, cost, drug, NICE, price, value | 5 Comments »
The National Institute for Health and Clinical Excellence (NICE) in the UK has issued a statement that, according to preliminary draft guidelines, it has rejected the use of sipuleucel-T (Provenge) to treat patients with metastatic prostate cancer before they have received chemotherapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, England, NICE, Provenge, sipuleucel-T, value | 3 Comments »
On Friday last week the National Institute for Health Care Excellence (NICE) in England came to the conclusion that abiraterone acetate (Zytiga) is not cost-effective in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC), based on the most recently proposed price to the National Health Service. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, approval, cost, enzalutamide, NICE | Leave a comment »
The National Institute for Health and Care Excellence (NICE) has issued final approval for coverage of treatment with enzalutamide (Xtandi) for men with metastatic, castrated-resistant prostate cancer (mCRPC) who have already received prior treatment with docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: coverage, enzalutamide, NICE, UK | 7 Comments »
The National Institute for Health and Clinical Excellence (NICE) in the UK has issued draft guidance and a media release stating that it can not justify recommending the use of abiraterone acetate for the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abirarterone, cost, enzalutamide, NICE | 13 Comments »
In a less than entirely surprising move, the UK’s National Institute for Health and Care Excellence has rejected Bayer’s initial application for coverage of radium-223 (Xofigo) under the National Health Service. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: access, NICE, radium-223 | 1 Comment »
According to a media release issued by the National Institute for Clinical Excellence (NICE) in the UK, it has issued new draft guidance recommending treatment with degarelix (Firmagon) as an option for men with prostate cancer-related spinal metastases who are at risk for spinal cord compression. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: compression, Degarelix, NICE, spinal cord | 6 Comments »
Patients in the UK will be pleased to hear that the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending reimbursement for enzalutamide (Xtandi) … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: enzalutamide, NICE | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 